Lecanemab treatment for Alzheimer's Disease of varying severities and associated serum biomarkers monitoring: a real‐world study
Bibliographic record
Abstract
BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia, posing significant global health and societal challenges. Lecanemab is a disease-modifying therapy approved for mild AD. In this report, we present real-world data on the efficacy and safety of lecanemab, and explore the role of AD-related serum biomarkers in monitoring treatment efficacy in a real-world setting. METHOD: Cognitive function was assessed using AD assessment scale-cognition (ADAS-Cog), clinical dementia rating scale-sum of boxes (CDR-SB), montreal cognitive assessment (MoCA), mini-mental state examination (MMSE), and frontal assessment battery (FAB) at baseline and every follow-up. Serum biomarkers, including neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), Aβ 1-40, Aβ 1-42, p-tau 181, and p-tau 217, were monitored with chemiluminescence assay at all time points. RESULT: Fifty-one AD patients meeting ATN criteria were enrolled (CDR 0.5: n = 25; CDR 1: n = 14; CDR 2: n = 12). Significant improvements were observed in ADAS-Cog (+4.36 points, p <0.001), CDR-SB (+0.31 points, p = 0.010), and MoCA (+1.40 points, p = 0.002) at 7 months, with no significant change in MMSE. Only serum p-tau 181 decreased significantly (p = 0.031), while p-tau 217 showed a non-significant trend. Spearman correlation analysis revealed associations between serum p-tau181, p-tau217, and cognitive scores. The adjusted linear mixed-effects model indicated a significant association between serum p-tau 181 and ADAS-Cog scores (β=0.3546, p <0.001). No serious adverse events occurred. Infusion reactions were reported in 7.69% of patients, and 9.62% discontinued due to asymptomatic amyloid-related imaging abnormalities (ARIA). CONCLUSION: In the real world, lecanemab may be safe and effective in the treatment of mild-to-moderate AD, and dynamic monitoring of serum p-tau 181 may be helpful to observe the efficacy during treatment. AD patients with severe cognitive impairment and significant white matter lesions should be closely monitored for adverse reactions, such as ARIA.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".